Lista de obras -

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

artículo científico publicado en 2017

A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma

artículo científico publicado en 2014

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

artículo científico publicado en 2016

Clinical Development of PD-1 Blockade in Hematologic Malignancies

artículo científico publicado en 2018

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes

artículo científico publicado en 2014

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs

artículo científico publicado en 2010

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma

artículo científico publicado en 2017

Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study

artículo científico publicado en 2021

Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation

artículo científico publicado en 2017

Harnessing the immune system for cancer therapy

artículo científico publicado en 2014

Hiding the road signs that lead to tumor immunity

artículo científico publicado en 2011

Immune checkpoint blockade for hematologic malignancies: a review

artículo científico publicado en 2017

Immunologic correlates of the abscopal effect in a patient with melanoma

artículo científico publicado en 2012

Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance

artículo científico publicado en 2017

Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.

artículo científico publicado en 2017

Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype

artículo científico publicado en 2012

Inhibition of chemokine expression by adenovirus early region three (E3) genes

artículo científico publicado en 2002

Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma

artículo científico publicado en 2019

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma

scientific article published on 01 June 2019

Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future

artículo científico publicado en 2020

Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma

Minimal residual disease in multiple myeloma: bringing the bench to the bedside

artículo científico publicado en 2015

Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition

scientific article published on 01 July 2019

Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action

artículo científico publicado en 2020

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment

artículo científico publicado en 2011

Myeloid-derived suppressor sells and the efficacy of CD8(+) T-cell immunotherapy

artículo científico publicado en 2013

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

artículo científico publicado en 2016

Nivolumab plus ipilimumab in advanced melanoma

artículo científico publicado en 2013

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

artículo científico publicado en 2009

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

artículo científico

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

artículo científico publicado en 2015

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma

artículo científico publicado en 2017

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab.

artículo científico publicado en 2014

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.

artículo científico publicado en 2013

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma

artículo científico publicado en 2016

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

artículo científico publicado en 2016

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.

artículo científico publicado en 2018

Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.

artículo científico publicado en 2017

Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response.

artículo científico publicado en 2009

Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies

scientific article published on 01 August 2019

Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample Database

scientific article published on 06 September 2018

Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity 1 with Novel Induction Regimens in Multiple Myeloma

artículo científico publicado en 2020

T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy

artículo científico publicado en 2015

Transjugular Liver Biopsy in a Multiple Myeloma Patient with Hepatomegaly, Portal Hypertension and "Miliary" Liver Lesions: A Case Report

artículo científico publicado en 2016

Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood

artículo científico publicado en 2016

Lista de obras de

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

Clinical Development of PD-1 Blockade in Hematologic Malignancies

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma

Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study

Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation

Harnessing the immune system for cancer therapy

Hiding the road signs that lead to tumor immunity

Immune checkpoint blockade for hematologic malignancies: a review

Immunologic correlates of the abscopal effect in a patient with melanoma

Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance

Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.

Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype

Inhibition of chemokine expression by adenovirus early region three (E3) genes

Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma

Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future

Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma

Minimal residual disease in multiple myeloma: bringing the bench to the bedside

Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition

Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment

Myeloid-derived suppressor sells and the efficacy of CD8(+) T-cell immunotherapy

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

Nivolumab plus ipilimumab in advanced melanoma

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab.

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.

Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.

Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response.

Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies

Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample Database

Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity 1 with Novel Induction Regimens in Multiple Myeloma

T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy

Transjugular Liver Biopsy in a Multiple Myeloma Patient with Hepatomegaly, Portal Hypertension and "Miliary" Liver Lesions: A Case Report

Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood